Bold claim: November 2025 quietly delivered big shifts in endocrinology that will shape how clinics treat weight, diabetes, and kidney health next year—and some of these developments are more controversial than they appear.
Here’s a rewritten, beginner-friendly synthesis of the original content, expanded with context and reader-friendly explanations while preserving all core information.
Trial results that matter
Novo Nordisk’s amycretin shows superior weight loss versus placebo
In late November 2025, Novo Nordisk announced positive results from a phase 2 trial of amycretin. The drug is designed to be given either once weekly by subcutaneous injection or once daily as an oral tablet, and it demonstrated meaningful weight loss and reductions in HbA1c for adults with type 2 diabetes. Building on these encouraging findings, the company plans to launch a phase 3 program in 2026 to confirm durability, safety, and real-world effectiveness.
Eloralintide outperforms placebo for weight management
Eloralintide, a once-weekly selective amylin receptor agonist, outperformed placebo in adults who are overweight or obese and have at least one related health condition. By influencing satiety and reducing daily calorie intake, Eloralintide targets the brain’s hunger signals. Researchers are also studying Eloralintide in combination with tirzepatide for broader weight-management scenarios, including those with obesity and type 2 diabetes.
Semaglutide contributes to cardiorenal benefits in CKD, with or without diabetes
A meta-analysis highlighted that semaglutide is associated with favorable safety outcomes for people with chronic kidney disease, regardless of diabetes status. Across five randomized trials, semaglutide reduced the risk of major adverse cardiovascular events, kidney-related complications, and cardiovascular death. These findings underscore the potential broad applicability of GLP-1-based therapies in nephrology and encourage further work to generalize GLP-1 data across diverse kidney diseases.
Other notable updates
Dexcom G7 and price changes for semaglutide discussed in Diabetes Dialogue
A Diabetes Dialogue episode covered Dexcom’s new 15-day G7 continuous glucose monitor, which launched through durable medical equipment channels on December 1 and is expected to roll out in pharmacies in January 2026. The G7 integrates with the existing Dexcom app and preserves the familiar accuracy, now with a longer wear period and a built-in 12-hour grace window. The segment also reviewed price revisions for Ozempic and Wegovy, noting discounts that temporarily reduce the first two months to $199 and subsequent months to $349 across all dose levels.
Semaglutide falls short in Alzheimer’s while tirzepatide shows promise in type 1 diabetes
Another Diabetes Dialogue episode examined Novo Nordisk’s setbacks in Alzheimer’s disease: oral semaglutide at 14 mg did not slow disease progression in the Evoke and Evoke+ phase 3 trials, though biomarker improvements were observed. As a result, a planned one-year extension was halted. In contrast, tirzepatide demonstrated notable benefits in weight loss and glycemic control in adults with type 1 diabetes in the TIRTLE phase 2 study, including reduced HbA1c and lower total daily insulin needs, without significant safety concerns.
Editorial note
HCPlive’s editors highlight five headlines from endocrinology in the last month—trials, real-world therapies, and the evolving roles of GLP-1–based medicines across multiple specialties. If you’re tracking how weight management drugs intersect with kidney disease, cardiovascular risk, and diabetes care, these stories illustrate a trend toward broader, cross-disciplinary applications rather than narrow, disease-specific use.
For clinicians and students, these updates emphasize:
- The ongoing expansion of GLP-1–based therapies beyond diabetes, including potential kidney and cardiovascular benefits.
- The importance of monitoring long-term outcomes in weight-management drugs, particularly when integrating with other obesity or diabetes regimens.
- The need to interpret biomarker improvements alongside actual disease progression outcomes in Alzheimer’s research and beyond.
Discussion prompts
- Should weight-loss meds with cardio-renal benefits be prioritized for early use in patients with obesity and prediabetic risk factors, even before diabetes develops? Why or why not?
- With Alzheimer’s trials showing biomarker gains but not slowed progression, how should clinicians weigh surrogate endpoints against real-world outcomes when evaluating new therapies?
- What considerations should guide the adoption of new sensors and pricing changes in diabetes care to balance patient access with innovation?
Would you like this rewritten summary tailored to a specific audience (e.g., patients, clinicians, investors) or adjusted for a particular word count or level of technical detail?
